Objective:

To evaluate the efficacy and safety of a once-weekly oral regimen combining islatravir and lenacapavir in patients with virologically suppressed HIV.

Approach:

Key Findings:

• The safety profile of islatravir/lenacapavir was generally comparable to the comparator regimens.

Interpretation:

Limitations:

• Islatravir and lenacapavir remain investigational and are not approved for use.

Conclusion:

Gilead and Merck plan to present findings at a scientific congress and file data with regulatory authorities globally.

Sources:

• Gilead and Merck Press Release
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.